Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation (Q34137853)

31 July 2017

1 reference

title

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation (English)

1 reference

31 July 2017

Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation (English)

0 references

1 reference

Andrew J Johnston

1

1 reference

31 July 2017

John Ascher

2

1 reference

31 July 2017

Robert Leadbetter

3

1 reference

31 July 2017

Virginia D Schmith

4

1 reference

31 July 2017

Dipak K Patel

5

1 reference

31 July 2017

Michael Durcan

6

1 reference

31 July 2017

Beth Bentley

7

1 reference

31 July 2017

Andrew J. Johnston

1

0 references

Virginia D. Schmith

4

0 references

Dipak K. Patel

5

0 references

publication date

1 January 2002

1 reference

31 July 2017

2002

0 references

published in

Drugs

1 reference

31 July 2017

62 Suppl 2

1 reference

31 July 2017

62

0 references

issue

Supplement 2

0 references

page(s)

11-24

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262002-00002

31 July 2017

0 references

cites work

Cigarette smoking among adults--United States, 1999

1 reference

12 December 2020

Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion.

1 reference

12 December 2020

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo

1 reference

12 December 2020

Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects

1 reference

12 December 2020

Bupropion to aid smoking cessation

1 reference

12 December 2020

Bupropion for smoking cessation : predictors of successful outcome

1 reference

12 December 2020

Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion

1 reference

12 December 2020

Trends in cigarette smoking in 36 populations from the early 1980s to the mid-1990s: findings from the WHO MONICA Project

1 reference

12 December 2020

Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.

1 reference

12 December 2020

Bupropion in depression. I. Biochemical effects and clinical response.

1 reference

12 December 2020

Alcohol and bupropion pharmacokinetics in healthy male volunteers

1 reference

12 December 2020

Role of dopamine in the behavioural actions of nicotine related to addiction

1 reference

12 December 2020

Nicotine dependence in the United States: prevalence, trends, and smoking persistence

1 reference

12 December 2020

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

1 reference

12 December 2020

Carbamazepine but not valproate induces bupropion metabolism.

1 reference

12 December 2020

Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.

1 reference

12 December 2020

Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression

1 reference

12 December 2020

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

1 reference

12 December 2020

Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine

1 reference

12 December 2020

Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender

1 reference

12 December 2020

Bupropion in Parkinson's disease.

1 reference

12 December 2020

The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion.

1 reference

12 December 2020

The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence

1 reference

12 December 2020

Bupropion: a review of its use in the management of smoking cessation

1 reference

12 December 2020

A hypothesis for a common neurochemical basis for alcohol and drug disorders.

1 reference

12 December 2020

Cigarette smoking and clinically significant drug interactions

1 reference

12 December 2020

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

1 reference

12 December 2020

Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease

1 reference

12 December 2020

Involvement of locus coeruleus projections in opiate withdrawal but not in opiate tolerance in mice.

1 reference

12 December 2020

The effect of bupropion on nicotine craving and withdrawal.

1 reference

12 December 2020

Recent trends and sociodemographic distribution of cardiovascular risk factors: results from two population surveys in the Austrian WHO CINDI demonstration area.

1 reference

12 December 2020

Bupropion: a review of its mechanism of antidepressant activity.

1 reference

12 December 2020

Towards a tobacco-free world

1 reference

12 December 2020

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation

1 reference

12 December 2020

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

1 reference

12 December 2020

A comparison of sustained-release bupropion and placebo for smoking cessation

1 reference

12 December 2020

Bupropion is a nicotinic antagonist.

1 reference

12 December 2020

10.2165/00003495-200262002-00002

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference